Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Round Table Discussions

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured

Published in Advanced Prostate Cancer and

Expert Opinion / Interview · May 16, 2016

Evolving Role of PSA Screening in Prostate Cancer

Interview by

Farzanna S Haffizulla MD, FACP, FAMWA

Interview with

Jonathan Silberstein MD, MBA

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

References

Notice to Our Valued Users

Advanced Prostate Cancer

Evolving Role of PSA Screening in Prostate Cancer

Additional Info

Further Reading

2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer

Impact of Salvage Radiotherapy Initiation at PSA ≤0.5 ng/mL on Survival Outcomes in Patients With Relapsed Prostate Cancer After Prostatectomy

Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations

PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Aggressiveness and Financial Toxicity in Patients With Prostate Cancer

VISION Trial Analysis of Time-to-Event Endpoints Associated With Radioligand Therapy

Androgen Annihilation in Patients With High-Risk, Biochemically Relapsed Prostate Cancer

Gene-Based Confirmatory Germline Testing Following Tumor-Only Sequencing of Prostate Cancer

Duration of Androgen Deprivation Therapy With Post-Operative Radiotherapy for Prostate Cancer

Abiraterone Plus Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer

SPOP Mutations as a Biomarker for Selecting Androgen Receptor Axis–Targeted Therapy in Patients With mCSPC

Related Videos